Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals

HBV vaccination effectively prevents HBV transmission and the development of liver cancer. Disease progression and liver-related complications are more common in HIV-1/HBV co-infected than HBV mono-infected individuals. A considerable body of literature, which will be reviewed here, indicates that r...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-12, Vol.9 (12), p.1484
Main Authors: Bekele, Yonas, Berzofsky, Jay A, Chiodi, Francesca
Format: Article
Language:English
Subjects:
Adults
anti-HBs antibodies
Antibodies
Antigens
Antiretroviral agents
Antiretroviral therapy
B cells
booster dose
CD4 antigen
Disease transmission
Drug dosages
Drug resistance
HBV
HBV vaccine
Hepatitis B
HIV
HIV-1
Human immunodeficiency virus
Immunocompetence
Immunology
Infections
Liver
Liver cancer
Liver diseases
Lymphocytes
Lymphocytes T
Mortality
Response rates
Review
Teenagers
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HBV vaccination effectively prevents HBV transmission and the development of liver cancer. Disease progression and liver-related complications are more common in HIV-1/HBV co-infected than HBV mono-infected individuals. A considerable body of literature, which will be reviewed here, indicates that response to HBV vaccine is suboptimal in HIV-1-infected individuals and that the poor maintenance of protective immunity to HBV vaccines in these individuals is an important medical issue. Several factors affect HBV vaccine response during HIV-1 infection including CD4+ T cell counts, B cell response, vaccine formulation, schedules, and timing of antiretroviral therapy (ART). The initial response to HBV vaccination also plays a critical role in the sustainability of antibody responses in both HIV-1-infected and uninfected vaccinees. Thus, regular follow-up for antibody titer and a booster dose is warranted to prevent HBV transmission in HIV-1 infected people.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9121484